Nonetheless, the use of TRPC4/TRPC5 inhibitors for cosmetic weight loss as well as to combat obesity, T2D, MS, NAFLD and non-alcoholic steatohepatitis was recently published (accession numbers: WO/2018/146485; EP3579838; US20200345741). Here, TRPC4 is linked to metabolic dysfunction-associated steatotic liver disease.